Harlan Robins Sells 14,233 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 14,233 shares of the company’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $16.52, for a total value of $235,129.16. Following the completion of the sale, the insider owned 1,155,291 shares in the company, valued at $19,085,407.32. This represents a 1.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Adaptive Biotechnologies Price Performance

NASDAQ:ADPT traded up $0.36 on Wednesday, reaching $16.44. The stock had a trading volume of 1,333,806 shares, compared to its average volume of 1,718,538. Adaptive Biotechnologies Corporation has a 12-month low of $6.26 and a 12-month high of $20.76. The company has a market cap of $2.53 billion, a price-to-earnings ratio of -41.10 and a beta of 2.19. The firm’s fifty day moving average is $16.85 and its two-hundred day moving average is $15.79.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.10. The business had revenue of $71.68 million for the quarter, compared to analysts’ expectations of $59.38 million. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The business’s revenue was up 51.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.23) earnings per share. As a group, research analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Key Headlines Impacting Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Company reported a quarterly earnings beat with strong revenue growth (revenue up ~51% YoY), which underpins the stock’s positive momentum. MarketBeat ADPT summary
• Positive Sentiment: Several sell-side firms raised price targets or reiterated Buy/Overweight ratings (Guggenheim, JPMorgan, Piper Sandler, Wall Street Zen), giving investors analyst support for higher valuations. Analyst coverage summary
• Neutral Sentiment: Reported short-interest entries show 0 shares (days-to-cover 0.0) — this appears to be a data error or non-material and shouldn’t be interpreted as meaningful short activity. (No actionable link.)
• Neutral Sentiment: Small institutional activity: several funds reported modest new or increased positions in the fourth quarter; institutional ownership remains high (~99%), so movements are incremental. MarketBeat ownership note
• Negative Sentiment: CEO Chad Robins executed multiple large sales in late Feb–early Mar (including 53,083 shares on Mar 3 and larger blocks on Mar 2 and Feb 27), reducing his stake materially; large insider sales can create short-term selling pressure or raise governance/insider-confidence questions. Chad Robins sale alert
• Negative Sentiment: Director/insider Harlan S. Robins also sold smaller blocks (10,000 and 14,233 shares on Mar 2–3), further increasing headline insider selling volume. Harlan S. Robins filings

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on ADPT shares. TD Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Guggenheim upped their price target on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Piper Sandler set a $21.00 price objective on Adaptive Biotechnologies in a research note on Friday, February 6th. JPMorgan Chase & Co. boosted their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Friday, February 6th. Finally, Morgan Stanley started coverage on shares of Adaptive Biotechnologies in a report on Monday, December 1st. They issued an “equal weight” rating and a $21.00 price target on the stock. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $18.25.

Institutional Investors Weigh In On Adaptive Biotechnologies

Large investors have recently added to or reduced their stakes in the company. XTX Topco Ltd acquired a new stake in Adaptive Biotechnologies during the 2nd quarter valued at approximately $793,000. SG Americas Securities LLC raised its position in shares of Adaptive Biotechnologies by 53.2% in the 2nd quarter. SG Americas Securities LLC now owns 37,328 shares of the company’s stock valued at $435,000 after purchasing an additional 12,963 shares in the last quarter. Allianz Asset Management GmbH boosted its stake in shares of Adaptive Biotechnologies by 305.8% during the 3rd quarter. Allianz Asset Management GmbH now owns 321,774 shares of the company’s stock valued at $4,814,000 after buying an additional 242,474 shares during the last quarter. Hillsdale Investment Management Inc. acquired a new stake in shares of Adaptive Biotechnologies during the second quarter worth approximately $6,618,000. Finally, Envestnet Asset Management Inc. bought a new stake in shares of Adaptive Biotechnologies in the second quarter worth $467,000. 99.17% of the stock is owned by institutional investors and hedge funds.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.